Chevy Chase Trust Holdings LLC Has $23.46 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Chevy Chase Trust Holdings LLC lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 316,921 shares of the medical research company’s stock after selling 13,472 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Edwards Lifesciences were worth $23,462,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Asset Planning Inc purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $1,993,000. Banque Pictet & Cie SA increased its stake in Edwards Lifesciences by 106.2% in the 4th quarter. Banque Pictet & Cie SA now owns 156,968 shares of the medical research company’s stock valued at $11,620,000 after buying an additional 80,851 shares during the last quarter. V Square Quantitative Management LLC increased its stake in Edwards Lifesciences by 2.3% in the 4th quarter. V Square Quantitative Management LLC now owns 15,374 shares of the medical research company’s stock valued at $1,138,000 after buying an additional 348 shares during the last quarter. Bogart Wealth LLC increased its stake in Edwards Lifesciences by 38.2% in the 4th quarter. Bogart Wealth LLC now owns 92,768 shares of the medical research company’s stock valued at $6,868,000 after buying an additional 25,657 shares during the last quarter. Finally, Asset Management One Co. Ltd. increased its stake in Edwards Lifesciences by 1.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 241,818 shares of the medical research company’s stock valued at $18,294,000 after buying an additional 2,426 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.3 %

EW opened at $76.23 on Friday. The company has a fifty day moving average price of $72.67 and a 200-day moving average price of $69.50. The firm has a market capitalization of $44.96 billion, a P/E ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Equities research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EW shares. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Morgan Stanley raised their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $79.95.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,489 shares of company stock worth $2,002,829. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.